ALKS 4230-Keytruda Combo Found to Reduce Tumor Size, Halt Disease Progression

ALKS 4230-Keytruda Combo Found to Reduce Tumor Size, Halt Disease Progression
The combination of Keytruda (pembrolizumab) and ALKS 4230 was able to halt disease progression and reduce tumor size in a small group of heavily pre-treated patients with advanced ovarian cancer, according to data from an ongoing Phase 1/2 trial. Findings from the trial, called ARTISTRY-1 (NCT02799095), also showed the combination therapy had a manageable safety and tolerability profile. Given these results, Alkermes, the developer of ALKS 4230, is now planning to launch a prospective study to evaluate the safety and effectiveness of this combination therapy in women with platinum-resistant ovarian cancer who also have been previously treated with bevacizumab. “Based on the durable complete and partial responses observed in the ARTISTRY-1 intravenous dosing study in tumor types with high unmet need and limited treatment options for patients, we are considering potential regulatory strategies that may support expeditious development paths in both monotherapy and combination settings,” Craig Hopkinson, MD, chief medical officer and executive vice president of research and development at Alkermes, said in a press release. A poster detailing the study's findings, titled “Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial,” was presented at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting, recently held online. ALKS 4230 is an investigational fusion protein made up of a modified version of interleukin-2 (IL-2), a molecule that's important for T-cell function, and the high-affinity IL-2 alpha receptor chain.  It's designed to promote the expansion and activation of cancer-killing immune cells, while preventing the activatio
Subscribe or to access all post and page content.